Clin2
NCT06943521Possibly a fitRecruiting

Study of MT-4561 for advanced solid tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Esophageal CancerGastric CancerBiliary Tract CancerPancreatic Ductal Adenocarcinoma (PDAC)Breast CancerOvarian Cancer

Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.

This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
27 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have a solid tumor (such as head and neck, lung, breast, or other types listed) that has not responded to at least one prior treatment, and no standard options are left, or you cannot tolerate or refuse further standard therapies.
  • You are 18 years or older.
  • You have at least one measurable tumor (can be seen on scans).
  • You are in good enough health to be up and about (ECOG score 0 or 1).
  • Your liver, kidney, and bone marrow function are adequate based on blood tests.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06242470Recruiting· Phase 1
Study of MGC026 for advanced solid tumors

This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.

Los Angeles, California
NCT04895709Recruiting· Phase 1/Phase 2
Testing a new cancer drug for advanced solid tumors

This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.

Clovis, California
NCT06810544Recruiting· Phase 1/Phase 2
Study of TNG456 for tumors with MTAP loss

This trial tests a new drug called TNG456, alone or with another drug (abemaciclib), for people whose tumors have lost the MTAP gene. It aims to see if the combination can shrink tumors or slow their growth.

Scottsdale, Arizona
NCT06400485Recruiting· Early Phase 1
Testing AMT-676 for advanced solid tumors

This trial tests a new drug called AMT-676 in people with advanced solid tumors that have not responded to standard treatments. It may be an option for those with certain cancers like colorectal, stomach, or pancreatic cancer.

Huntersville, North Carolina
NCT06985355Recruiting· Phase 1/Phase 2
Testing MHB046C injection for advanced solid tumors

This trial tests an experimental drug called MHB046C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.

Guangzhou, Guangdong
NCT07231211Recruiting· Phase 1/Phase 2
Testing SHR-4610 for advanced solid tumors

This trial tests a new drug called SHR-4610 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective, and may be an option if you have a measurable tumor and are generally in good health.

Hangzhou, Zhejiang

Hear when a new Esophageal Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.